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ABSTRACT: Novel lipid derivatives carrying amino and triazolyl groups were efficiently synthesized 
and covalently anchored at the 3’-termini of oligonucleotides. The desired amino lipid-conjugates were 
fully characterized by reverse phase HPLC and MALDI-TOF mass spectrometry. The methodology was 
applied to the synthesis of lipid-siRNA designed to inhibit tumor necrosis factor (TNF-a) in order to 
obtain siRNAs with anti-inflammatory properties. The siRNA duplex carrying amino-lipids at the 3’-
end of the passenger strand has similar inhibitory properties to unmodified RNA duplexes in HeLa cells 
indicating that the new lipid derivatives are compatible with the RNA interference machinery.  
KEYWORDS: RNA interference, oligonucleotides, chemically modified siRNA, lipids, click chemistry, 
guanidinium, post-synthetic approach, covalent strategy, TNF-α 
 
INTRODUCTION 
 
RNA interference (RNAi) plays an important role in host defense and regulation of gene expression. 
Since RNAi was discovered a decade ago by Fire et al.,1 RNA research has seen intense growth. During 
RNA interference, double-stranded RNAs are processed into small fragments of approximately 21 
nucleotides by the enzyme Dicer2 that are incorporated into the RNA-induced silencing complex (RISC) 
directing the degradation of specific complementary mRNA sequences.3 The introduction of short 
interfering RNAs (siRNA) in mammalian cells3 results in a selective silencing of the protein encoded by 
the specific mRNA targeted by siRNA. Since then, researchers have been actively looking for different 
approaches to enhance this powerful tool in order to be used in therapeutics.4 However, successful 
therapeutic applications have been delayed due to delivery problems since native siRNAs do not freely 
diffuse across the cell membrane due to their relatively large molecular weight and their polyanionic 
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nature. To overcome these limitations, different strategies have been employed and non-viral vectors 
have emerged as a promising alternative to gene delivery. 5 
The most used carriers for DNA and RNA oligonucleotides are cationic lipids and liposomes which 
promote cellular uptake of antisense and RNAi therapies6 although their mechanism is still unclear and 
controversial. In general, the use of targeted lipoplexes as systems to mediate siRNA delivery has 
become the most reported method.7,8 These units, which maintain an electrostatic association, are often 
unstable9 and should be prepared before use, so other alternative and robust linkage methods between 
siRNAs and non-viral vectors may be developed and validated. Recently it has been demonstrated that 
nanoparticles can be used for the efficient delivery of siRNA.10  
Lipid-oligonucleotide conjugates are an interesting alternative. Some years ago, lipid-oligonucleotide 
conjugates were found to improve biological activity of triplex-forming and antisense 
oliognucleotides.11 Recently, a few examples on the use of siRNA covalently conjugated to lipids have 
been described in the literature. Cholesterol,12 fatty acids derivatives12 and α-tocopherol13 have been 
efficiently linked to the 5’-ends (phosphoramidite chemistry) and 3’-ends (CPG supports) of the siRNA 
guide and passenger strands. Further biological evaluations of these conjugates showed that the 
introduction of these groups did not affect the RNAi machinery obtaining high levels of inhibition in the 
gene expression. 
As a part of our ongoing interest in the development of chemically modified DNA and siRNAs to 
inhibit gene expression,14 we have been looking into the possibility of synthesizing siRNA conjugates 
by linking lipid molecules with different polar and / or protonatable groups (such as amines and 
triazoles) at the 3’-termini of the siRNA duplex (Scheme 1). We aimed to mimic the effect produced by 
lipoplex complexes. As far as we know, such complex lipids have never been introduced into siRNA. 
Finally, the effects of such modifications on the RNAi machinery were measured through the evaluation 
of these chemically modified lipid-siRNA conjugates in the regulation of the TNF-α gene expression.     
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SCHEME 1. Structure of the lipid oligonucleotide conjugates described in this study. 
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RESULTS AND DISCUSSION 
Synthesis of the lipid derivatives. The introduction of lipids to the 3’ end of oligonucleotides needs the 
use of a linker that connects the lipid to the growing DNA chain. Aminodiols such 4-aminoprolinol12a, 
12d and trihydroxy compounds such as glycerol12c have been used for this purpose. Aminodiols are used 
to incorporate fatty acids by formation of an amide bond that is stable to oligonucleotide synthesis 
conditions12d. Moreover, aminodiols such as 4-aminoprolinol12d have the advantage of well defined 
chirality. But the use of this type of linkers needs the use of fatty acids functionalized at the other end of 
the hydrocarbon chain for the preparation of amino-lipids. These compounds are not easily available. In 
contrast, trihydroxy compounds can be used if ether or urethane bonds are used to connect the lipid to 
the triols. In these cases the resulting lipid derivatives usually generate diastereoisomeric mixtures, but 
the presence of isomers are not considered a serious problem for biological activity of the resulting 
siRNA. Moreover disubstituted alkanes needed for the preparation of the lipid derivatives are available.  
For these reasons we considered the use of a glycerol backbone (Scheme 1) as suitable linker for 
introducing our chemical modifications at the 3’-end of the siRNA duplexes. This linker when reacted 
with phosphoramidites will produce a phosphate bond that will be stable to ammonia deprotection 
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conditions used in oligonucleotide synthesis. Also, it allows the incorporation of the lipid derivative to a 
solid support.  The synthesis of lipidic solid-supports 7, 15 and 16 is outlined in Schemes 2 and 3. All 
compounds were obtained from the same intermediate azide 3 which was synthesized from 
commercially available (rac)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol as starting material. The 
synthesis started with the alkylation reaction between solketal 1 and commercially available 1,12-
dibromododecane in DMF in the presence of sodium hydride (60%) which primarily yielded the 
alkylated compound 2. However, the presence of a side compound was also observed. This side 
compound may arise from the E2 elimination of HBr (dehydrohalogenation). To avoid this, we started 
an alkylation reaction of 1 via di-n-butylstannylene in the presence of 2.0 equiv of cesium fluoride15  in 
the presence of DMF, providing 2 in 47% yield after purification by flash chromatography and without 
detecting any trace of that impurity.  
 
SCHEME 2.   Synthesis of solid-support 7 functionalized with amino C12 
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Reagents and Conditions: a. i . di-n-butyl tin oxide, MeOH, reflux; i i . CsF, 1,12-Dibromododecane, 60 ºC; b. NaN3, DMF, 70 ºC; c. Boc2O, TEA, DCM, r.t.; 
d. i. DCM/TFA 10%, r.t.; i i . ETFA, TEA, DCM, 0ºC; e. DMTr, DMAP, Py, 40 ºC; e. CPG derivatization
 
The nucleophilic displacement of the bromide group with sodium azide in DMF yielded the desired 
azide 3 in 93% yield. Having on hand azide 3, subsequent reduction under Staudinger conditions gave 
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the expected amine which was conveniently protected with Boc2O in standard conditions achieving the 
N-Boc-protected 4 in 65% yield. Finally, the introduction of the 4,4’-dimethoxytrityl (DMTr) protecting 
group was easily obtained by removing acetonide and N-Boc moieties simultaneously under acidic 
conditions (DCM:TFA 3%) followed by N-protection with ethyl trifluoroacetate thereby yielding the N-
protected compound 5 in 87% yield. DMTr protection with DMAP in the presence of pyridine afforded 
the desired trityl derivative 6 in 58% yield after purification by flash chromatography. 
Click chemistry, on the other hand, is considered to be a modular approach that is increasingly found in 
all aspects of drug discovery, combinatorial chemistry and recently, in nucleic acid chemistry16, easily 
obtaining triazolyl rings.17 Taking this into account, we considered exploring the use of the 1,3-dipolar 
cycloadditions between the previously synthesized azide 3 and some commercially available alkynes18 
in order to study the subsequent effect that these kind of rings could exercise on the RNAi machinery. 
Then, the click reactions were carried out under standard conditions19 to give the desired triazoles 
compounds 8 and 9 as only regioisomers in 89% and 59% yield respectively after purification by flash 
chromatography (Scheme 3).  
In order to obtain the corresponding trityl derivatives, compounds 8 and 9 were subjected to acetonide 
hydrolysis in different acid conditions (DCM:TFA 3% for acetonide 8; pTsOH in the presence of 
methanol for acetonide 9, respectively) yielding the requisite diols 10 and 11 in 72% and 99% yield 
respectively. Trityl derivative 13 was directly obtained from protecting alcohol 10 with DMTr under the 
same conditions previously mentioned in 39% yield. Finally, the synthesis of last trityl derivative 14 
was carried out as follows: the phthalimide 11 was removed under basic hydrolysis to give the expected 
amine which was then subsequently protected with ethyl trifluoroacetate yielding the N-protected amine 
12. Finally, the selective protection of primary alcohol 12 with 4-monomethoxytrityl (MMTr) afforded 
the corresponding protected trityl alcohol 14 in 45% yield. 
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SCHEME 3. Click chemistry and synthesis of the solid-supports 15 and 16 
 
 
Reagents and Conditions: a. selected alkynes, 10% sodium ascorbate, CuSO4·5H2O, tBuOH:H2O (1:1), r.t., overnight; b. i. (for 8): DCM:TFA 3%, r.t.; 
(for 9): pTsOH, MeOH, r.t.; c. i . MeNH2, EtOH, 40 ºC, overnight; ii . ETFA, TEA, DCM, 0 ºC; d. (for 13): DMTr, DMAP, pyridine, 40 ºC, overnight; (for 14):
MMTr, DMAP, pyridine, 40 ºC, overnight.; e. CPG derivatization
ne
c
12    R = Tfa and n = 4 
n
n
d
n
4 a b
10    R = Fmoc and n = 1 ; 11    R = phthal imide and n = 4 
selected alkynes
16    R1 = Fmoc, R2 = DMTr and n = 1
15    R1 = Tfa, R2 = MMTr and n = 4
9    R = Fmoc and n = 1 
8    R = phthalimide and n = 4 
14    R1 = Fmoc, R2 = DMTr and n = 1
13    R1 = Tfa, R2 = MMTr and n = 4 
 
The three trityl compounds 6, 13 and 14 were coupled with CPG supports using the succinyl linker as 
described.20 For this purpose, the DMTr and MMTr-derivatives described above reacted with succinic 
anhydride followed by coupling the resulting hemisuccinates with amino-functionalized CPG which 
yielded glass beads containing lipids 7 (21 µmol/g), 15 (25 µmol/g) and 16 (23 µmol/g), respectively. 
CPG functionalization was determined by the measure of the absorbance of the DMTr / MMTr cations 
released from the support upon acid treatment. 
 
Oligodeoxyribonucleotide synthesis. First, we synthesized a short oligodeoxynucleotide sequence to 
demonstrate the stability of the lipid derivative to phosphoramidite synthesis conditions.  The self-
complementary Dickerson-Drew dodecamer sequence (5’-CGCGAATTCGCG-3’) was used as a model 
sequence. The sequence was assembled on CPG solid supports 7, 15 and 16 using standard protocols in 
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order to generate the corresponding lipid-oligonucleotide conjugates by using DMT off- based protocols. 
After cleavage with ammonia solution (32%) followed by HPLC purification the corresponding 
modified aminolipid-oligonucleotide conjugates (17-19) were obtained and confirmed by MALDI-TOF 
mass spectrometry (MS) (Table 1). 
TABLE 1. Mass spectrometry and melting temperatutes (Tm) of lipid-modified oligonucleotides 
prepared in this study.  
Oligonucleotide Sequence 5’ à 3’ MW calc MW found Tm (ºC)* 
17 CGCGAATTCGCG-C12NH2 3983 3982.5 55 
18 CGCGAATTCGCG-C12-triazol-CH2NH2 4066 4065 58 
19 CGCGAATTCGCG-C12-triazol-(CH2)4NH2 4106 4105 57 
20 CGCGAATTCGCG-C12NHC(NH)-NH2 4027 4029 61 
21 CGCGAATTCGCG-C12-triazol-CH2NHC(NH)-NH2 4108 4109 56 
22 CGCGAATTCGCG-C12-triazol-(CH2)4NHC(NH)-NH2 4150 4151 55 
23 GUGCCUAUGUCUCAGCCUCTT-C12NH2 6896 6899 n.d. 
24 GUGCCUAUGUCUCAGCCUCTT- C12-triazol-CH2NH2 6977 
6991            
[M+Na+] n.d. 
25 GUGCCUAUGUCUCAGCCUCTT- C12-triazol-(CH2)4NH2 7019 
7054 
[M+2Na+] n.d. 
*conditions: sodium phosphate 10 mM, NaCl NaCl, pH 7.0, in these conditions unmodified Dickerson-
Drew dodecamer melted at 49 ºC; n.d. not determined. 
 
In addition, we studied the conversion of the amino group to the guanidinium group in order to extend 
the possibility of cationic charge enrichment in our synthesized aminolipid-oligonucleotide conjugates 
17-19. The synthesis of certain guanidinium derivatives of nucleic acids has been described in the 
literature21 and some of them have been synthesized through post-synthetic modification.14a,21e The 
guanidinium-modified ONs synthesized during this study are summarized on Table 1. In all cases, 
selective and quantitative guanidinylation were observed following a classical post-synthetic 
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approach21e on oligonucleotides  17-19 which were reacted with O-methylisourea for 16 hr at 55ºC. 
After desalting, the guanidinylated compounds 20-22 (Scheme 4) were analyzed by analytical HPLC 
and characterized by MALDI experiments. Melting temperatures of the synthesized lipid-modified 
dodecamers were higher than unmodified dodecamer (see Table 1). A similar effect has been also 
observed recently with the dodecamer modified with arginine and lysine residues as well as lipids.14b.  
 
SCHEME 4. Synthesis of the amine and guanidinium oligonucleotides  
 
CGCGAATTCGCG
5' 3'
a CGCGAATTCGCG
5' 3'
Reagents and Conditions. a. i . O-Methylisourea chloride, NH3 (32%), 55 ºC, overnight
17-19 20-22
 
 
 
Oligoribonucleotide synthesis. All oligoribonucleotides were synthesized using solid supports 7, 15 
and 16 (1.0 µmol each) using a DNA/RNA synthesizer (sequences of guide and passenger strands are 
shown in Tables 1 and 2). Modified RNA oligonucleotides linked to the aforementioned solid supports 
were released according to DMT on- based protocols and then crude modified oligoribonucleotides were 
first purified by HPLC followed by DMTr deprotection with AcOH 80%. Finally, amino lipid-RNA 
conjugates (23-25) were again analyzed by reversed phase HPLC and characterized by MALDI-TOF 
mass spectrometry (Table 1). siRNA duplexes (siRNA2, siRNA3 and siRNA4, respectively) were 
obtained by annealing of equal molar amounts of passenger (sense) and guide (antisense) strands, which 
were purified by ethanol precipitation protocol (see Experimental Part). 
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TABLE 2. Sequences of unmodified, lipid-modified and scrambled siRNA sequences used in this study 
 
siRNA Sequences* 
Unmodified 
(siRNA-1) 
              GUGCCUAUGUCUCAGCCUCTT 
         TTCACGGAUACAGAGUCGGAG 
siRNA-2 
              GUGCCUAUGUCUCAGCCUCTT-C12NH2 
        TTCACGGAUACAGAGUCGGAG 
siRNA-3 
              GUGCCUAUGUCUCAGCCUCTT-C12-triazol-CH2NH2 
         TTCACGGAUACAGAGUCGGAG 
siRNA-4 
              GUGCCUAUGUCUCAGCCUCTT-C12-triazol-(CH2)4NH2 
       TTCACGGAUACAGAGUCGGAG 
Scrambled 
(siRNA-5) 
              CAGUCGCGUUUGCGACUGGTT 
         TTGUCAGCGCAAACGCUGACC 
*siRNAs are shown with the passenger strand above (5’ – 3’) and the guide strand below (3’ – 5’). T 
stands for thymidine. 
 
Gene silencing by modified siRNAs. The gene silencing effect on the TNF-α messenger RNA of 
several siRNAs: one native siRNA1, three chemically modified siRNAs (siRNA2, siRNA3 and 
siRNA4) and one scrambled siRNA5 were studied. HeLa cells were first co-transfected with plasmid 
pCAm TNF-α by using commercial cationic liposomes (Lipofectamine-2000). We then carried out the 
transfection of the aforementioned siRNA derivatives with oligofectamine. Forty-eight hours after 
transfection, the amount of TNF-α produced by the cells was analyzed by enzyme-linked 
immunosorbent assay (ELISA). The silencing activities are depicted on Figure 1. In general, all 
chemically modified siRNAs previously obtained maintained their abilities to down-regulate TNF-α 
protein expression levels to around 65% at 50 nM concentration compared with the scrambled control 
siRNA5 duplex. These results indicate that the introduction of all the proposed modifications at the 3’-
termini of the passenger strand of an RNA duplex is compatible with the RNAi machinery in HeLa 
cells.   
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FIGURE 1. Efficiency of silencing of chemically modified siRNAs with lipids in the passenger strand 
 
 
 
Plot of gene-specific silencing activities for native (siRNA-1), chemically modified conjugates (siRNA-2, siRNA-3 and 
siRNA-4) and scrambled sequence (siRNA-5) (50 nM per well). Transfection of siRNA conjugates was carried out by using 
Lipofectamine 2000 and Oligofectamine (see above). Values are represented the average ±ES, n = 3 and are compared to a 
scrambled sequence. ***p<0.001, ANOVA Test, Bonferrini post-test.  
 
 
CONCLUSIONS 
In general, the most common method of administration of siRNAs in cell culture is based on the use of 
non-viral vectors such as cationic lipids. The interaction between siRNA and cationic lipids is due to the 
existence of electrostatic interactions and the formation of lipoplexes. Notwithstanding, the use of a 
covalent strategy between the aforementioned siRNA and cationic lipids is also possible, though in most 
of the cases only neutral lipids have been linked to siRNA. Following this approach, we have reported a 
convenient synthesis by which glycerolipid based structures with different polar groups have been 
efficiently synthesized and introduced into the 3’-termini of the siRNA sense strand being the first time 
that oligonucleotides carrying cationic lipids are reported. The amino group of the lipid can be used for 
the generation of guanidinium groups and also for further functionalization to proteins, liposomes, 
nanoparticles and so on. Finally, we were able to confirm all these proposed modifications did not affect 
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the RNAi machinery through silencing TNF-α gene expression.  
 
EXPERIMENTAL SECTION 
Abbreviations: ACN, acetonitrile; AcOEt, ethyl acetate; Boc, t-butoxycarbonyl; Boc2O, di-t-butyl 
dicarbonate; tBuOH, t-butanol; Ch, cyclohexane; CPG, controlled pore glass; DCM, dichloromethane; 
DMF, N,N-dimethylformamide, DMAP: N,N-dimethylaminopyridine; DMTr: 4,4’-dimethoxytrityl; 
EtOH, ethanol; ETFA, ethyl trifluoroacetate; Fmoc, 9-fluorenylmethoxycarbonyl; MeOH, methanol; 
MMTr,  4-monomethoxytrityl; Py: pyridine; TEA, triethylamine; TNF-a, tumor necrosis factor; TFA, 
trifluoroacetic acid; Tfa: trifluoroacetyl; TsOH: p-toluenesulfonic acid. 
 
Materials and Methods. All reactions were carried out under argon positive pressure in anhydrous 
solvents. Commercially available reagents and anhydrous solvents were used without further 
purification. Solvents were distilled prior to use and dried using standard methods. Analytical samples 
were homogeneous as confirmed by TLC and yielded spectroscopic results were consistent with the 
assigned structures. Chemical shifts are reported in parts per million (ppm) relative to the singlet at δ = 
7.24 ppm of CHCl3 for 1H NMR and to the centre line of the triplet at δ = 77.0 ppm of CDCl3 for 13C 
NMR. IR spectra were measured in film. Thin-layer chromatography (TLC) was performed on silica gel 
(Alugram Sil G/UV).  
HPLC conditions. Conditions for semipreparative HPLC: HPLC solutions were solvent A: 5%  
acetonitrile (ACN) in 100 mM triethylammonium acetate (TEAA), pH 6.5 and solvent B: 70 % ACN in 
100 mM triethylammonium acetate (pH 6.5). Column: PRP-1 (Hamilton) 250x 10 mm. Flow rate 3 
ml/min linear gradient from 15 to 100% in B (DMTon) and 0 to 50% in B (DMToff) was used with UV 
detection at 260 nm. Conditions for analytical HPLC: HPLC solutions were solvent A: 5% acetonitrile 
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(ACN) in 100 mM triethylammonium acetate (TEAA), pH 6.5 and solvent B: 70 % ACN in 100 mM 
triethylammonium acetate (pH 6.5). Column: XBridge OST C18 2.5 μm. Flow rate 1ml/min linear 
gradient from 0 to 50% in B (DMToff) were used with UV detection at 260 nm. 
 
4-((12-bromododecyloxy)methyl)-2,2-dimethyl-1,3-dioxolane, 2. Alcohol 1 (200 mg; 1.51 mmol) was 
reacted with dibutyltin oxide (751 mg, 3.02 mmol; 2.0 eq) in dry methanol (10 mL) at reflux for 3h, 
followed by removing the methanol and any traces of water using azeotropic distillation with toluene. 
The reaction mixture was concentrated and then, 1,12-dibromododecane (991 mg, 3.02 mmol; 2.0 eq), 
cesium fluoride (458 mg, 3.02 mmol; 2.0 eq) and dry DMF (10 mL) were added. The reaction mixture 
was kept at room temperature overnight. The solvent was evaporated and the resulting residue was 
purified by flash chromatography (Ch:AcOEt 1% to 4%): Yield: 47%; IR (film) 2989, 2931, 2858, 
1455, 1367, 1255, 1212, 1115, 1054, 845 cm-1; 1H-NMR (400 MHz, CDCl3) δ 4.24 (q, J = 6.0 Hz, 1H, 
CH-O), 4.03 (dd, J = 14.6 Hz, 8.2 Hz; 1H, O-CH-CH), 3.71 (dd, J = 8.2 Hz, 14.6 Hz; 1H, O-CH-CH), 
3.49 (m, 2H, CH2-O), 3.40 (m, 2H, CH2-O), 3.38 (t, J = 6.8 Hz, 2H, CH2-Br), 1.83 (q, J = 7.1 Hz, 2H, 
CH2-CH2), 1.55 (m, 2H), 1.40 (s, 3H, CH3-C), 1.34 (s, 3H, CH3-C), 1.25 (m, 16H); 13C-NMR (125 
MHz, CDCl3) δ 109.9 (O-C-CH3), 75.4 (CH-O), 72.5 (O-CH2), 72.4 (CH2-O), 67.5 (CH2-O), 34.6 
(CH2-Br), 33.4, 30.2, 30.1, 30.1, 30.0, 30.0, 29.4, 28.8, 27.4, 26.6, 26.0; HR ESI MS: m/z calcd for 
C18H35BrO3 Na (M + Na), 401.1661; found, ; m/z 401.1662; calcd for C36H70O6NaBr2 Na (2M + Na), 
779.3427; found, 779.3431. 
4-((12-azidododecyloxy)methyl)-2,2-dimethyl-1,3-dioxolane, 3. Compound 2 (100 mg, 0.264 mmol) 
was dissolved in 5 mL of anhydrous DMF. NaN3 (103 mg, 1.58 mmol; 6.0 eq) was then added and the 
mixture was stirred and heated to 70 ºC for 48 h. The reaction was cooled at 0ºC and water was added 
carefully. The solvent was evaporated and the resulting oil was then purified by flash chromatography 
(Ch:AcOEt 1% to 3%): Yield: 93%; IR (film) 2935, 2858, 2363, 2344, 2093, 1251, 1077 cm-1; 1H-NMR 
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(400 MHz, CDCl3) δ 4.26 (q, J = 6.1 Hz, 1H, CH-O), 4.06 (dd, J = 14.6 Hz, 8.23 Hz; 1H, O-CH-CH), 
3.72 (dd, J = 8.22 Hz, 14.6 Hz; 1H, O-CH-CH), 3.51 (m, 2H, CH2-O ), 3.43 (m, 2H, CH2-O), 3.25 (t, J 
= 6.97 Hz, 2H, CH2-N3), 1.59 (m, 6H), 1.42 (s, 3H, CH3-C), 1.36 (s, 3H, CH3-C), 1.27 (m, 14H); 13C-
NMR (125 MHz, CDCl3) δ 109.3 (O-C-CH3), 74.7 (CH-O), 71.8 (O-CH2), 71.7 (O-CH2), 66.9 (O-CH2), 
51.4 (CH2-N3), 29.5, 29.4, 29.4, 29.4, 29.4, 29.1, 28.7, 26.7, 26.6, 26.0, 25.3; HR ESI MS: m/z calcd for 
C18H36N3O3 (M+), 342.2755; found, m/z 342.2751; calcd for C18H35N3O3K (M + K), 380.2312; found, 
380.2310. 
tert-butyl 12-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)dodecylcarbamate, 4. Azide 3 (85 mg, 0.249 
mmol) along with PPh3 (131 mg, 0.498 mmol; 2.0 eq) were dissolved in 3 mL of anhydrous THF. The 
reaction was stirred for 2 hours at room temperature. Subsequently, water (500 uL) was added dropwise. 
The mixture was stirred overnight at room temperature. The solvent was evaporated and the crude was 
dried by pressure, yielding the anticipated amine. This amine was dissolved in 2.0 mL of anhydrous 
DCM; TEA (69 μL, 0.498 mmol; 2.0 eq) was added dropwise along with Boc2O (82 mg, 0.373 mmol; 
1.5 eq). The reaction was stirred for 5 hours at room temperature. The organic layer was extracted with 
more DCM (5 mL) and rinsed with water (3 x 10 mL). The organic layer was dried on anhydrous 
Na2SO4. The solvent evaporated and the resulting residue was purified by flash chromatography 
(Ch:AcOEt 4% to 9 %): Yield: 65%; IR (film) 3020, 2935, 2850, 1699, 1506, 1371, 1216, 1166, 1046 
cm-1; 1H-NMR (400 MHz, CDCl3) δ 4.49 (broad s, 1H), 4.26 (m, 1H, CH-O), 4.04 (dd, J = 14.6 Hz, 8.2 
Hz; 1H, O-CH-CH), 3.72 (dd, J = 14.6 Hz, 8.2 Hz; 1H, O-CH-CH), 3.50 (m, 2H, CH2-O), 3.42 (m, 2H, 
CH2-O), 3.08 (m, 2H, CH2-N), 1.56 (m, 2H), 1.43 (s, 9H, 3 CH3-C), 1.41 (s, 3H, CH3-C), 1.35 (s, 3H, 
CH3-C), 1.24 (m, 18H); 13C-NMR (125 MHz, CDCl3) δ 158.8 (CO), 110.0 (OCCH3), 75.4 (CH-O), 
72.5 (O-CH2), 72.4 (O-CH2), 67.6 (O-CH2), 30.7 (N-CH2), 30.2, 30.1, 29.9, 29.1, 27.4, 27.4, 26.7, 26.1; 
HR ESI MS: m/z calcd for C23H45NO5 (M + H+), 416.3370; found, m/z 416.3370. 
N-(12-(2,3-dihydroxypropoxy)dodecyl)-2,2,2-trifluoroacetamide, 5. Compound 4 (60.0 mg, 0.161 
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mmol) was dissolved in a mixture of DCM/TFA 10% (5 mL) at room temperature for 20 minutes. The 
solvent evaporated yielding the corresponding trifluoroacetate in its salt form. The resulting oil was then 
dissolved in anhydrous DCM (5.0 mL) and TEA was added dropwise (45 μL, 0.322 mmol). The 
reaction was cooled at 0ºC and ethyl trifluoroacetate (22.0 μL, 0.177 mmol) was added. The reaction 
was stirred for 30 minutes, extracting the organic layer with more DCM (3 x 10 mL) and rinsed with 
water (3 x 10 mL). The organic layer was dried with anhydrous Na2SO4. The solvent evaporated and the 
resulting oil was purified by flash chromatography (DCM:MeOH 2%): Yield: 87 %; IR (film) 3333, 
2924, 2854, 1694, 1552, 1471, 1185 cm-1; 1H-NMR (400 MHz, CDCl3) δ 6.42 (broad s, 1H), 3.05 (m, 
1H, CH-O), 3.72 (dd, J = 11.4 Hz, 3.8 Hz; 1H, O-CH-CH), 3.65 (dd, J = 11.4 Hz, 5.2 Hz; 1H, O-CH-
CH), 3.51 (m, 2H, CH2-O), 3.49 (m, 2H, CH2-O), 3.35 (m, 2H, CH2-NHCO), 1.57 (m, 2H), 1.26 (m, 
20H); 13C-NMR (125 MHz, CDCl3) δ 157.8 (q, J = 36.9 Hz, COCF3), 117.9 (q, J = 287.6 Hz, CF3), 73.2 
(CH-O), 72.5 (O-CH2), 71.0 (O-CH2), 64.9 (O-CH2), 40.6 (NHCO-CH2), 30.2, 30.1, 30.1, 30.1, 30.0, 
29.7, 29.6, 27.3, 26.7; 19F-NMR (CDCl3) δ -76.3 (reference CFCl3); HR ESI MS: m/z calcd for 
C17H32F3NO4Na (M + Na+), 394.2175; found, m/z 394.2176. 
N-(12-(3-(bis(4-methoxyphenyl)(phenyl)methoxy)-2-hydroxypropoxy)dodecyl)-2,2,2-
trifluoroacetamide, 6. Compound 5 (52 mg, 0.140 mmol) along with DMTrCl (48 mg, 0.141 mmol; 
1.2 eq) and DMAP (8 mg, 0.07 mmol; 0.5 eq) were dissolved in 1.5 mL of anhydrous pyridine. The 
reaction was heated at 40 ºC and stirred overnight. Methanol (0.5 mL) was added and the solvent 
evaporated. The resulting product was purified by flash chromatography (Hex/AcOEt 15%): Yield: 
58%; IR (film) 3276, 3072, 2927, 2851, 1716, 1673, 1607, 1502, 1462, 1390, 1248, 1176, 1038 cm-1; 
1H-NMR (400 MHz, CDCl3) δ 7.67 (m, 3H, phenyl), 7.40 (m, 2H, phenyl), 7.28 (m, 3H, phenyl), 7.01 
(broad s, 1H), 6.81 (d, J = 8.9 Hz, 4H, phenyl), 3.92 (m, 1H, CH-O), 3.76 (s, 6H, 2 CH3), 3.52 (dd, J = 
9.7 Hz, 4.2 Hz; 1H, CH-CH2-O), 3.43 (m, 3H, CH-CH2-O), 3.35 (m, 2H, CH2-O), 3.17 (m, 2H, CH2-
NH), 2.41 (broad d, 1H), 1.85 (m, 2H), 1.57 (m, 9H), 1.25 (m, 9H); 13C-NMR (125 MHz, CDCl3) δ 
162.7, 158.6, 149.9, 145.0. 136.3, 136.2, 130.2, 128.3, 127.9, 126.9, 123.9, 113.2, 86.2, 72.3, 71.8, 70.1, 
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64.7, 55.4, 55.3, 55.3, 50.8, 40.2, 36.6, 31.6, 29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 29.6, 29.3, 29.1, 26.8, 
26.2; 19F-NMR δ -74.3 (reference CFCl3); HR ESI MS: m/z calcd for C38H50F3NO6Na (M+ Na+)), 
696.3482; found, m/z 696.3490. 
General procedure for the click reaction (8 and 9). Azide 3 (1.0 eq) and selected alkynes (1.0 eq) 
were suspended in a 1:1 mixture of water and tert-butyl alcohol (1.0 mL). Sodium ascorbate (10%) and 
copper (II) sulphate pentahydrate (1%) were added dropwise. The heterogeneous mixture was stirred 
vigorously overnight. The reaction mixture was diluted with DCM and the organic layer was washed 
with water (3x5 mL). The organic layer was dried with anhydrous Na2SO4 and solvent evaporated. The 
resulting oil was purified by flash chromatography. 
2-(4-(1-(12-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)dodecyl)-1H-1,2,3-triazol-4-
yl)butyl)isoindoline-1,3-dione, 8. Yield: 89%; IR (film) 2919, 2854, 2363, 2342, 1710, 1053 cm-1; 1H-
NMR (400 MHz, CDCl3) δ 7.81 (m, 2H, phenyl), 7.69 (m, 2H, phenyl), 7.27 (s, 1H, CH=C), 4.27 (t, J = 
7.24 Hz; 2H, CH2-O), 4.22 (m, 1H, CH-O), 4.04 (dd, J = 14.6 Hz, 8.2 Hz; 1H, CH-CH2-O), 3.69 (m, 
3H), 3.49 (m, 2H), 3.41 (m, 2H), 2.74 (t, J = 7.0 Hz, 2H, CH2-N), 1.85 (m, 2H), 1.72 (m, 4H), 1.54 (m, 
2H), 1.40 (s, 3H, CH3-C), 1.34 (s, 3H, CH3-C), 1.26 (m, 16H); 13C-NMR (125 MHz, CDCl3) δ 168.6 
(CO), 134.1 (phenyl), 132.3 (phenyl), 123.3 (phenyl), 121.0 (C=N), 120.6 (CH-N) 109.5 (O-C-CH3), 
74.9 (CH-O), 72.1 (CH-CH2-O), 72.0 (CH-CH2-O), 67.1 (CH-CH2-O), 50.4 (CH2-C=), 37.8 (CH2-
NCO), 30.5 (CH2-N), 29.7, 29.7, 29.7, 29.6, 29.5, 29.2, 28.2, 26.9, 26.8, 26.7, 26.2, 25.6, 25.3; HR ESI 
MS: m/z calcd for C32H48N4O5 (M++1), 569.3697; found, m/z 569.3697 calcd for C32H48N4O5 Na (M + 
Na+), 591.3516; found, m/z 591.3516. 
 (9H-fluoren-9-yl)methyl-(1-(12-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)dodecyl)-1H-1,2,3-
triazol-4-yl)methylcarbamate, 9. Yield: 58%; IR (film) 2930, 2858, 1721,1523, 1448, 1370, 1250, 
1120, 1049, 758, 738 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.5 Hz; 2H, phenyl), 7.57 (d, J = 
7.5 Hz; 2H, phenyl), 7.47 (s, 1H, CH=C), 7.38 (t, J = 7.3Hz; 2H, phenyl), 7.29 (t, J = 7.4 Hz; 2H, 
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phenyl), 5.48 (broad d, 1H, NH), 4.46 (d, J = 6.0 Hz; 2H, CH2-OCO), 4.40 (d, J = 7.0 Hz; 2H, CH-CH2-
O), 4.31 (t, J = 7.2 Hz; 1H, O-CH-C), 4.25 (t, J =  6.0 Hz; 2H, CH2-O), 4.22 (m, 2H), 4.05 (dd, J = 14.6 
Hz, 8.2 Hz; 1H, CH-O-C), 3.72 (dd, J = 14.6 Hz, 8.2 Hz; 1H, CH-O-C), 3.50 (m, 2H), 3.42 (m, 2H), 
1.87 (m, 2H), 1.55 (m, 2H), 1.41 (s, 3H, CH3-C), 1.35 (s, 3H, CH3-C), 1.27 (m, 16H); 13C-NMR (125 
MHz, CDCl3) δ 156.3 (CO), 143.8 (phenyl), 141.2 (phenyl), 127.6 (phenyl), 127.0 (CH=C), 125.0 
(C=C), 119.9 (phenyl), 109.3 (O-C-O), 74.7 (CH-O), 71.9 (CH-CH2-O), 71.8 (CH-CH2-O), 66.9 (CH2-
O), 50.3 (O-CH2-C), 47.2 (C-CH2-NCO), 36.5 (C-CH2), 30.2, 29.5, 29.5, 29.4, 29.4, 29.3, 28.9, 26.7, 
26.4, 26.0, 25.4; HR ESI MS: m/z calcd for C36H50N4O5 (M++1), 619.3853; found, ; m/z 619.3858; calcd 
for C36H50N4O5 Na (M + Na+), 641.3673; found, m/z 641.3675. 
(9H-fluoren-9-yl)methyl-(1-(12-(2,3-dihydroxypropoxy)dodecyl)-1H-1,2,3-triazol-4-
yl)methylcarbamate, 10. Compound 9 (48 mg; 0.078 mmol) was dissolved in a mixture of CH2Cl2 / 
TFA 3% (2.5 mL). The reaction was stirred at room temperature for 30 minutes. The solvent was 
reduced to dryness, washing three times with more CH2Cl2. The resulting compound was purified by 
flash chromatography (CH2Cl2 / MeOH 2%): Yield: 72%; IR (film) 3329, 2926, 2858, 1715, 1522, 
1441, 1256, 1127, 1043, cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz; 2H), 7.58 (d, J = 7.3 
Hz; 2H), 7.38 (t, J = 7.3 Hz; 2H), 7.28 (m, 3H), 5.83 (broad s, 1H), 5.31 (s, 2H), 4.64-4.13 (m, 5H), 3.76 
(m, 4H), 3.47 (m, 4H), 1.89 (m, 2H), 1.56 (m, 2H), 1.26 (m, 16H); 13C-NMR (400 MHz, CDCl3) δ 
156.4, 143.6, 141.1, 127.5, 126.8, 124.9, 119.8, 72.3, 71.6, 70.3, 70.2, 66.7, 64.0, 53.2, 50.6, 47.0, 29.9, 
29.5, 29.3, 29.2, 29.2, 29.2, 29.2, 29.1, 28.7, 26.3, 25.8; HR ESI MS: m/z calcd for C33H47N4O5 (M++1), 
579.3540; found, m/z 579.3539 calcd for C33H46N4O5 Na (M + Na+), 601.3360; found, m/z 601.3358. 
2-(4-(1-(12-(2,3-dihydroxypropoxy)dodecyl)-1H-1,2,3-triazol-4-yl)butyl)isoindoline-1,3-dione, 11.  
Compound 8 (30 mg, 0.052 mmol; 1.0 eq) along with pTsOH (5 mg, 0.026 mmol; 0.5 eq) were 
dissolved in methanol (1.0 mL). The reaction was stirred at room temperature for 5 hours. The methanol 
evaporated and the resulting oil was purified by flash chromatography (CH2Cl2:MeOH 2%): Yield: 
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99%; IR (film) 3349, 2924, 2850, 1684, 1517, 1251, 1170, 1123, 1046 cm-1; 1H-NMR (400 MHz, 
CDCl3) δ 7.82 (m, 2H), 7.69 (m, 2H), 7.28 (s, 1H), 4.27 (t, J = 7.2 Hz; 2H), 3.85 (m, 1H), 3.69 (m, 3H), 
3.63 (m, 1H), 3.49 (m, 2H), 3.44 (m, 2H), 2.74 (m, 2H), 2.53 (broad d, 2H), 1.85 (m, 2H), 1.72 (m, 4H), 
1.55 (m, 2H), 1.23 (m, 18H); 13C-NMR (400 MHz, CDCl3) δ 168.6, 134.1, 132.3, 123.4, 72.7, 72.0, 
70.6, 64.4, 50.4, 37.8, 30.5, 29.7, 29.6, 29.6, 29.6, 29.5, 29.5, 29.1, 28.2, 26.8, 26.6, 26.2, 25.3; ; HR 
ESI MS: m/z calcd for C29H44N4O5 (M++1), 529.3384; found, m/z 529.3384; calcd for C29H44N4O5 Na 
(M + Na+), 551.3190; found, m/z 551.3200. 
N-(4-(1-(12-(3-(bis(4-methoxyphenyl)(phenyl)methoxy)-2-hydroxypropoxy)dodecyl)-1H-1,2,3-
triazol-4-yl)butyl)-2,2,2-trifluoroacetamide, 13. Compound 11 (30 mg, 0.060 mmol) was dissolved in 
1.0 mL of ethanol. Then, 80 µL of MeNH2 was added dropwise. The mixture was stirred overnight at 40 
ºC. The solvent was reduced to dryness and the resulting product was dissolved again in anhydrous 
DCM (1.5 mL). TEA (38uL) was added dropwise at room temperature. The reaction was cooled at 0ºC 
and EFTA (8.0 uL) was added dropwise. The reaction was stirred for 30 minutes at 0ºC. The organic 
layer was washed with water and brine (3 x 10 mL) and dried with anhydrous Na2SO4 and evaporated. 
The resulting compound was used in the next step without further purification. The compound obtained, 
along with MMTrCl (27.8 mg, 0.09 mmol; 1.5 eq) and DMAP (4.0 mg, 0.03 mmol; 0.5 eq) were 
dissolved in 1.0 mL of pyridine. The reaction was heated at 40 ºC and stirred overnight. Methanol was 
added (1.0 mL) and the solvent evaporated. The product was then purified by flash chromatography 
(DCM/MeOH/TEA 98:1:1): Yield: 39%; IR (film) 3065, 2935, 2860, 1715, 1650, 1593, 1454, 1230, 
cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.41 (m, 2H), 7.31 (m, 4H), 7.26 (m, 4H), 6.82 (d, J = 8.8 Hz, 4H), 
4.29 (t, J = 7.2 Hz; 2H), 3.94 (m, 1H), 3.78 (s, 6H), 3.51 (m, 2H), 3.42 (m, 4H), 3.17 (m, 2H), 2.99 (m, 
3H), 2.74 (t, J = 7.0 Hz, 2H), 1.87 (m, 2H), 1.75 (m, 2H), 1.67 (m, 2H), 1.53 (m, 2H), 1.28 (m, 16H); 
13C-NMR (400 MHz, CDCl3) δ 158.6, 150.0, 147.4, 145.0, 136.2, 130.2, 128.3, 128.0, 126.9, 124.0, 
123.8 (q, J = 298.1 Hz, CF3), 120.9, 113.2, 86.2, 72.3, 71.8, 70.1, 64.6, 55.4, 50.4, 39.8, 30.5, 29.8, 
29.7, 29.6, 29.5, 29.2, 28.1, 26.7, 26.4, 26.3, 24.9; 19F-NMR δ -73.5 (reference CFCl3); HR ESI MS: m/z 
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calcd for C44H59F3N4O6 (M + H+), 796.4434; found, m/z 796.44353 calcd for C44H59F3N4O6Na (M++23), 
819.3745; found, m/z 819.3742. 
 (9H-fluoren-9-yl)methyl-(1-(12-(2-hydroxy-3-((4-methoxyphenyl)-diphenylmethoxy)-propoxy)-
dodecyl)-1H-1,2,3-triazol-4-yl)methylcarbamate, 14. 10 (32 mg; 0.055 mmol) along with DMAP (3 
mg; 0.0275 mmol; 0.5 eq) and MMTrCl (26 mg, 0.083 mmol; 1.5 eq) were dissolved in pyridine (1.5 
mL). The reaction was heated at 40 ºC and stirred overnight. Methanol (1.0 mL) was added and the 
solvent was evaporated. The resulting compound was purified by flash chromatography (CH2Cl2:MeOH 
1%): Yield: 45%; IR (film) 3064, 2930, 2855, 1726, 1607, 1505, 1449, 1252, 1074, 755 cm-1; 1H-NMR 
(400 MHz, CDCl3) δ 7.69 (d, J = 7.5 Hz; 1H), 7.50 (d, J = 7.5 Hz; 1H), 7.35 (m, 4H), 7.21 (m, 4H), 7.13 
(m, 1H), 6.73 (d, J = 8.9 Hz; 1H), 5.37 (m, 1H), 4.38 (dd, J = 22.9 Hz, 5.8 Hz; 4H), 4.18 (m, 4H), 3.87 
(m, 1H), 3.71 (s, 3H), 3.45 (m, 2H), 3.38 (m, 2H), 3.10 (m, 2H), 2.48 (c, J = 7.2 Hz; 2H), 1.80 (m, 2H), 
1.46 (m, 2H), 1.18 (m, 16H); 13C-NMR (400 MHz, CDCl3) δ 158.8, 156.6, 144.6, 144.0, 141.5, 135.7, 
130.5, 128.7, 128.6, 128.0, 127.9, 127.2, 1271, 125.2, 122.2, 120.0, 113.3, 86.5, 72.3, 71.8, 70.0, 67.0, 
64.7, 55.4, 50.6, 47.4, 46.4, 36.7, 30.4, 29.8, 29.7, 29.7, 29.6, 29.5, 29.2, 26.7, 26.7, 26.3; HR ESI MS: 
m/z calcd for C53H62N4O6Na (M + Na+), 873.4558; found, m/z 873.4555 calcd for C106H124N8O12 Na 
(2M++23), 1723.9230; found, m/z 1723.9234. 
Synthesis of amine oligonucleotides (17-19). Oligonucleotide synthesis was carried out in an 
automated DNA synthesizer on a 1.0 μmol scale using CPG resins 7, 15, 16. The synthesis followed the 
regular protocol for the DNA synthesizer. After a final detritylation, the oligonucleotides were removed 
from the universal solid support by treatment with concentrated ammonia at 55 °C for 20 h. After 
desalting (Sephadex G-25, NAP-10), pure aminolipid-oligonucleotide conjugates 17-19 were obtained. 
Synthesis of guanidin-oligonucleotides (20-22). Amine oligonucleotides 20-22 (about 2.0 OD) were 
treated with a mixture (60 μL)  of a O-Methylisourea chloride prepared solution (50 mg, 0.40 mmol) in 
water (50 μL) and an aqueous ammonia (30%, 60 μL). The reaction mixtures were incubated overnight 
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at 55 ºC. The water evaporated and crude was desalted (Sephadex G-25, NAP-5), yielding the 
corresponding guanidine-oligonucleotides 20-22 in a pure form. 
Melting Experiments. UV melting experiments were carried out on a UV spectrometer. Samples were 
dissolved in a medium salt buffer containing Na2HPO4 (5 mM), NaH2PO4 (10 mM), NaCl (100 mM). 
The increase in absorbance at 260 nm as a function of time was recorded while the temperature was 
increased linearly from 20 to 90 °C at a rate of 0.5 °C/min by means of a Peltier temperature 
programmer. The melting temperature was determined by the local maximum of the first derivatives of 
the absorbance vs. temperature curve. All melting curves were found to be reversible. All 
determinations are averages of triplicates. 
Oligoribonucleotide synthesis. The following RNA sequences were obtained from commercial sources 
(Sigma-Proligo, Dharmacon): sense or passanger scrambled 5’-CAGUCGCGUUUGCGACUGGTT-3’; 
antisense or guide scrambled 5’-CCAGUCGCAAACGCGACUGTT-3’; sense or passenger anti-TNF-α: 
5’-GUGCCUAUGUCUCAGCCUCTT-3’ and antisense or guide anti-TNFα: 5’-GAGGCUGAGAC-
AUAGGCACTT-3’. Trityl derivatives 6, 13 and 14 were coupled to the CPG solid supports, according 
to the literature.20 Modified CPG solid supports 7, 15 and 16 were then employed in the preparation of 
RNAs strands using a DNA/RNA synthesizer. Modified siRNAs sense strands were purified using 
DMT on- based protocols: RNAs were cleaved from the support with a mixture of concentrated 
ammonia and ethanol 3:1 at 55 ºC for 60 minutes. Solvent was evaporated to dryness and 1M solution 
of TBAF in THF was added. RNAs were incubated 24 hours at room temperature. The deprotection 
reaction was quenched and modified RNA conjugates were desalted (Sephadex, NAP-10) and purified 
by semi-preparative HPLC. Finally, DMTr groups were deprotected (AcOH 80%, 30 min), extracted 
them with ether and finally, chemically modified RNA conjugates 24, 25 and 26 were desalted 
(Sephadex G-25, NAP-5) and characterized by MALDI-TOF mass spectrometry.   
siRNA duplexes.  The chemically modified sense or passanger strand and antisense or guide strand 
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RNAs were dissolved in a buffer 10 mM TRIS 50 mM NaCl (100µL). Different aliquots were taken. 
For each sample, buffer is added until having a final volume of 100 µL. Modified siRNAs (siRNA-2, 
siRNA-3 and siRNA-4, respectively) were heated at 94 ºC for two minutes and they let to cool until 
reaching room temperature. Then, 3M NaOAc pH = 5.2 was added (10 µL) along with EtOH (96%) 
(275 µL). Samples were stirred, centrifuged at 4 ºC (15 minutes, 12000 rpm) and precipitated at -20 ºC. 
Finally, the supernatant was removed and the respective pellets were carefully dried with argon.         
Cell culture and siRNA conjugates treatments. HeLa cells were cultured under standard conditions 
(37ºC, 5% CO2, Dulbecco’s Modified Eagle Medium, 10% fetal bovine serum, 2mM L-glutamine, 
supplemented with penicillin (100 U/ml) and streptomycin (100 mg/ml).  All experiments were 
conducted at 40-60% confluence. HeLa cells were transfected with 250 ng of the plasmid expressing 
murine TNF-α plasmid using lipofectin (Invitrogen), following the manufacturer’s instructions. One 
hour after transfection, m-TNF-α expressing HeLa cells were transfected with 50nM of native siRNA 
(23), chemically modified siRNA-2, siRNA-3, siRNA-4 and scrambled siRNA-5 against TNF-α, using 
oligofectamine (Invitrogen). The TNF-α concentration was determined from cell culture supernatant by 
enzyme-linked immunoabsorbent assay kit (ELISA, Bender MedSystems) following the manufacturer’s 
instructions.  
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